Cecilie Bahnsen Reimagines PORTER's Nylon Bags With Laser-Cut Florals
Leading the collection is the backpack, available in an all-black nylon twill and decorated with black-on-black embroidery throughout the body and laser-cut flowers — Bahnsen's signature. The 2 Way Tool Bag, offered in classic olive green Khaki, a baby Gratian Blue, and Black, is a more directional silhouette, combining the likenesses of an elegant handbag and a tool carrier into one model. Finally, the smallest piece is the Bonsac Mini, offered in the same colorways, with a scaled-down design.
On the new collaboration, Bahnsen said, 'This is a romantic act. It's about sorting through memories while deciding what to keep and what to reconstruct,' in a statement. Highlighting the power of quiet charm over flashy displays, Bahnsen's monochrome approach gives PORTER's durable nylon fabrics the spotlight. Simultaneously, the romantic sensibilities of the collection represent a contemporary facet of PORTER's visual identity as it inches towards 100 years in business.
The Cecilie Bahnsen x PORTER collection is set for release on June 5 at PORTER's flagship store, PORTER SHINJUKU, andYoshida & Co.'s web store.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Russ Buckley Appointed Group Chief Risk Officer at Hamilton
PEMBROKE, Bermuda--(BUSINESS WIRE)--Hamilton Insurance Group, Ltd. (NYSE: HG) ('Hamilton' or the 'Company') today announced the appointment of Russ Buckley as Group Chief Risk Officer. Buckley will join the Company's Executive Management team, reporting to Pina Albo, Chief Executive Officer, with the official start date in the coming weeks to be confirmed. In his new role, Buckley will oversee Hamilton's risk and actuarial function. He will succeed current Group Chief Risk Officer Alex Baker who, as the Company recently announced, has been appointed Chief Executive Officer, Hamilton Global Specialty, effective September 1, 2025, subject to regulatory approval. 'Russ is an experienced insurance leader with strong business acumen, drive and a track record of success,' said Albo. 'Having worked directly with Russ in the past, I look forward to again enjoying his results-driven mindset, commitment to excellence and collaborative approach — qualities that align well with Hamilton's culture. Together with our exceptional risk and actuarial team, Russ will be able to hit the ground running.' Buckley has over 30 years of insurance industry experience across global public (re)insurance companies. He joins Hamilton from Old Republic Specialty Insurance Underwriters, Inc. where he served as Senior Vice President and Chief Actuarial Officer since 2020. Prior to that, Buckley was Chief Actuary in the Global Specialty division at The Hartford. Additionally, Buckley has held leadership positions with AIG, XL, and Munich Reinsurance Group. He is a Fellow of the Casualty Actuarial Society. About Hamilton Insurance Group, Ltd. Hamilton is a Bermuda-headquartered specialty insurance and reinsurance company that underwrites risks on a global basis through its wholly owned subsidiaries. Its three underwriting platforms: Hamilton Global Specialty, Hamilton Select and Hamilton Re, each with dedicated and experienced leadership, provide access to diversified and profitable business around the world. For more about our company, visit or find us on LinkedIn at Hamilton.
Bloomberg
4 hours ago
- Bloomberg
JPMorgan Names New Global Co-Head of Blockchain Division
JPMorgan Chase & Co. has appointed a new global co-head of its blockchain division Kinexys. Based in Edinburgh, Kara Kennedy will lead Kinexys alongside Naveen Mallela, according to a JPMorgan spokesperson. Kennedy will oversee Kinexys Digital Assets, which focuses on asset tokenization, and Kinexys Labs, which helps clients prototype blockchain projects. Mallela, who is based in Singapore, will continue to run the payments divisions, including Kinexys Digital Payments and Kinexys Liink.
Yahoo
5 hours ago
- Yahoo
Novo Nordisk to advance ATTR amyloidosis mAb to Phase III
Novo Nordisk will advance its acquired ATTR amyloidosis with cardiomyopathy monoclonal antibody (mAb) to Phase III trials. The Danish pharma said that the Phase II trial of coramitug (PRX004), an mAb designed to deplete amyloid deposits, was 'successfully completed'. The trial investigated the efficacy and safety of once-monthly intravenous (IV) doses of coramitug compared to placebo in 105 patients with ATTR-cardiomyopathy. The primary endpoints of the trial included the functional endpoints of a six-minute walking test (6MWT), as well as a change in NT-proBNP after 52 weeks of treatment. While data has not yet been released, Novo Nordisk said results will be available at a medical conference later this year. However, the drugmaker confirmed its intention to initiate a Phase III trial of the drug in ATTR with cardiomyopathy before the end of 2025 in its Q2 2025 earnings call on 6 August. The news will be a welcome financial development for Prothena Corporation after the drug was acquired from them by Novo Nordisk in July 2021. Under the agreement, Prothena is eligible to receive up to $1.2bn upon achievement of clinical development and sales milestones, including the $100m earned to date. While NovoNordisk stocks have dropped on 6 August, in part due to the Q2 and H1 earnings announcement, Prothena's stock has risen slightly on the news, up from $7.03 at market close on 5 August to $7.45 at market open on 6 August – a 5.97% rise. Prothena's CEO Dr Gene Kinney said: 'We are excited by Novo Nordisk's decision to advance coramitug into Phase III development. There remains a significant unmet need in patients with ATTR amyloidosis with cardiomyopathy, who are at high risk for early mortality and significant morbidity due to amyloid deposition in vital organs.' ATTR successes and failures In May 2025, Prothena faced a trial setback after a Phase III study of birtamimab in patients with amyloid light-chain (AL) amyloidosis missed its primary endpoint. During the same month, Intellia Therapeutics' stock crashed after a serious adverse event (AE) in a Phase III trial of its ATTR cardiomyopathy gene therapy. Despite this event, trials of the therapy are ongoing. US biopharma Alnylam is celebrating a recent win, however, after its ATTR cardiomyopathy drug Amvuttra (vutrisiran) gained approval by the European Commission on 11 June. This came three months after the therapy got the green light from the US Food and Drug Administration (FDA) in March 2025. Other approved therapies include Pfizer's Vyndamax (tafamidis) and BridgeBio Pharma's Attruby (acoramidis). After the EC approval of Amvuttra, GlobalData cardiovascular and metabolic diseases analyst Costanza Alciati said the approval marked a change in the treatment paradigm for these patients, with therapies such as coramitug and ALXN2220 also set to have an impact. "Novo Nordisk to advance ATTR amyloidosis mAb to Phase III " was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
